News

The United States Patent and Trademark Office (USPTO) just granted our patent that protects LIM109 and its uses in inflammatory and neurodegenerative diseases. This is an important step in our IP strategy since the USA market is one of the most important ones in the...

The United States Patent and Trademark Office (USPTO) just granted our patent that protects LIM21 and its uses in ocular diseases. This is an important step in our IP strategy since the USA market is one of the most important ones in the world.

Limnopharma has been awarded as one of the 5 finalists in the Startup Andalucía Roadshow program, awarding the most innovative startups companies in Andalucia. The other awardees have been Myhixel, OWO games, Scoobic Urban Mobility and Wuolah. The five winners will...

Limnopharma is awarded with a Research Project funded by the NEOTEC program (CDTI; Spanish Ministry of Science and Innovation), for new Business Projects from innovative Start-up companies. The project granted includes a series of experiments for the preclinical...

Limnopharma signs a Research Agreement with “Fundación Progreso y Salud”, an organization which belongs to the Andalusian Region Ministry of Health (Spain). The agreement includes the execution of the “Lead retina” research project, led by Dr. Dr. Díaz-Corrales, to...

On August 1st, 2020, Limno hires Dr. Elena Puerta-Fernández as company’s CEO. Elena holds a Pharmacy degree and PhD. in Biochemistry and Molecular Biology by the University of Granada. She has a research career longer than 20 years, with wide international experience....

Limno was selected to participate in the program “Misión Directa a Boston”, a program funded by Extenda- Agencia Andaluza de Promoción Exterior, from the Andalusian Government to promote the internalization of Andalusian start-up companies. Boston is one of the more...